Cellosaurus logo
expasy logo

Cellosaurus YUL-PR2 (CVCL_C8TK)

[Text version]
Cell line name YUL-PR2
Accession CVCL_C8TK
Resource Identification Initiative To cite this cell line use: YUL-PR2 (RRID:CVCL_C8TK)
Comments Selected for resistance to: ChEBI; CHEBI_195559; Poziotinib (HMB781-36B).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Asn771delinsPheHis (N771delinsFH); Zygosity=Unspecified (from parent cell line).
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_C8TI (YUL-0019)
Category Cancer cell line
Publications

PubMed=35820397; DOI=10.1016/j.ccell.2022.06.006; PMCID=PMC9667883
Yasir Yousif Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiu-Ning Le, Marcelo Vailati Negrao ...Show all 27 authors... , Monique B. Nilsson, Anisha Patel, Ramaswamy S.K. Vijayan, Jason B. Cross, Jian-Jun Zhang, Lauren Averett Byers, Charles Lu, Tina Cascone, Lei Feng, Rajyalakshmi Luthra, Francis Anthony San Lucas, Geeta Mantha, Mark J. Routbort, George R. Blumenschein Jr., Anne S. Tsao, John Victor Heymach; Show fewer authors
Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Cancer Cell 40:754-767.e6(2022)

Cross-references
Encyclopedic resources Wikidata; Q123033992
Entry history
Entry creation05-Oct-2023
Last entry update19-Dec-2024
Version number3